R.A., Aftab A.H., Khan A.S., Adnan S.A.S., Sulaiman T.M., Khan Supplementary Material for: Assessment of Losartan 50 mg on Survival of Post-Dialysis Euvolemic Hypertensive Patients: Findings from HELD Trial <b><i>Aims and objective:</i></b> To estimate the effect of losartan 50 mg on survival of post-dialysis euvolemic hypertensive patients. <b><i>Methodology:</i></b> A single center, prospective, single-blind randomized trial was conducted to estimate the survival of post-dialysis euvolemic hypertensive patients when treated with lorsartan 50 mg every other day. Post-dialysis euvolemic assessment was done by a body composition monitor. Covariate Adaptive Randomization was used for allocation of participants to the standard or intervention arm, and the follow-up duration was twelve months. The primary end point was achieving targeted blood pressure (BP) of <140/90 mm Hg and maintaining for 4 weeks, whereas secondary end point was all cause of mortality. Pre-, intra-, and post-dialysis session BP measurements were recorded, and survival trends were analyzed using Kaplan-Meier analysis. <b><i>Results:</i></b> Of the total 229 patients, 96 (41.9%) were identified as post-dialysis euvolemic hypertensive. Final samples of 88 (40.1%) patients were randomized into standard (<i>n</i> = 44) and intervention arms (<i>n</i> = 44), and 36 (81.8%) patients in each arm completed a follow-up of 12 months. A total of eight patients passed away during the 12-month follow-up period (6 deaths among standard arm and 2 in intervention arm). However, the probability of survival between both arms was not significant (<i>p</i> = 0.13). Cox regression analysis revealed that chances of survival were higher among the patients in the intervention (OR 3.17) arm than the standard arm (OR 0.31); however, the survival was found not statistically significant. <b><i>Conclusion:</i></b> There was no statistical significant difference in 1 year survival of post-dialysis euvolemic hypertensive patients when treated with losartan 50 mg. Blood pressure;Losartan;Kaplan-Meier estimate;Hypertension 2019-08-06
    https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Assessment_of_Losartan_50_mg_on_Survival_of_Post-Dialysis_Euvolemic_Hypertensive_Patients_Findings_from_HELD_Trial/9267887
10.6084/m9.figshare.9267887.v1